<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02403986</url>
  </required_header>
  <id_info>
    <org_study_id>CTN 05DF1404</org_study_id>
    <nct_id>NCT02403986</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study Evaluating Treatment Sessions of Restylane Skinboosters Vital Lidocaine in the Face</brief_title>
  <official_title>A Randomised, Multi-centre, Parallel-group, Efficacy and Safety Study Evaluating Two and Three Initial Treatment Sessions of Restylane Skinboosters Vital Lidocaine in the Face</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised, multi-centre, parallel-group efficacy and safety study evaluating two and three
      initial treatment sessions of Restylane Skinboosters Vital Lidocaine in the face.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 50 female subjects shall be treated with two or three initial treatment
      sessions including long-term follow-up 18 months after the initial treatment regimen.
      Efficacy and safety to be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">March 30, 2017</completion_date>
  <primary_completion_date type="Actual">March 30, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Improved Participants on the Global Aesthetic Improvement Scale (GAIS)-Subject</measure>
    <time_frame>Baseline, 1 Month, 3 Months, 6 Months, 9 Months, 12 Months, 15 Months, 18 Months</time_frame>
    <description>Subject assessment at follow-up visits of aesthetic change from baseline of the treated areas using the Global Aesthetic Improvement Scale (GAIS).
GAIS is a 5-graded scale: worse; no change; improved; much improved; or very much improved.
A clinically significant improvement was defined as a score of improved; much improved; or very much improved.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Improved Participants on the Global Aesthetic Improvement Scale (GAIS)-Investigator</measure>
    <time_frame>Baseline, 1 Month, 3 Months, 6 Months, 9 Months, 12 Months, 15 Months, 18 Months</time_frame>
    <description>Investigator assessment at follow-up visits of aesthetic change from baseline of the treated areas using the Global Aesthetic Improvement Scale (GAIS).
GAIS is a 5-graded scale: worse; no change; improved; much improved; or very much improved.
A clinically significant improvement was defined as a score of improved; much improved; or very much improved.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Aged Skin</condition>
  <arm_group>
    <arm_group_label>R. Vital Skinboosters Lidocaine (three)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with three initial sessions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R. Vital Skinboosters Lidocaine (two)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with two initial sessions</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane Vital Skinboosters Lidocaine</intervention_name>
    <arm_group_label>R. Vital Skinboosters Lidocaine (three)</arm_group_label>
    <arm_group_label>R. Vital Skinboosters Lidocaine (two)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated informed consent to participate in the study.

          -  Non-pregnant, non-breast feeding female aged 35-45 years.

          -  Visible signs of aging in the face

          -  Intent to improve skin hydration, skin structure and the elasticity of the skin using
             - Restylane Skinboosters Vital Lidocaine.

        Exclusion Criteria:

          -  Extensively photo damaged and aged skin.

          -  Woman who plan to become pregnant during the course of the study.

          -  Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel.

          -  Known/previous allergy or hypersensitivity to local anaesthetics, e.g. lidocaine or
             other amide-type anaesthetics.

          -  History of severe or multiple allergies manifested by anaphylaxis.

          -  History of bleeding disorders or treatment with anticoagulants or inhibitors of
             platelet aggregation, Omega-3 or Vitamin E within 10 days before study treatment

          -  Treatment with chemotherapy, immunosuppressive agents, immunomodulatory therapy (e.g.
             monoclonal antibodies), systemic or topical (facial) corticosteroids (inhaled
             corticoids are allowed) within three months before study treatment.

          -  Previous tissue augmenting therapy or contouring with permanent filler or
             fat-injection in the face.

          -  Previous tissue augmenting therapy, contouring or revitalisation treatment with
             non-permanent filler, neurotoxin or revitalisation preparations (e.g. Hyal System or
             Restylane Skinboosters) in the face within 12 months before study treatment.

          -  Previous tissue revitalisation treatment with laser or light, radiofrequency, focused
             ultrasound, chemical peeling, dermabrasion, mesotherapy or any other similar treatment
             with influence on skin quality in the face within 6 months before study treatment.

          -  Previous aesthetic facial surgical therapy, liposuction or tattoo in the face.

          -  Previous sinus surgery or dental root surgery within 3 months before study treatment.

          -  Active skin disease, inflammation or related conditions, such as infection, perioral
             dermatitis, seborrheic eczema, rosacea, acne, psoriasis or herpes zoster in the face.

          -  History of or active collagen diseases or autoimmune diseases such as systemic lupus
             erythematosus, rheumatic arthritis, skin or systemic sclerosis.

          -  Tendency to form keloids, hypertrophic scars or any other healing disorder.

          -  History of radiation of or cancerous or pre-cancerous lesions (e.g. actinic keratosis)
             in the face.

          -  Use of systemic or facial topical retinoic acid within 12 months before study
             treatment.

          -  Nicotine use within 6 months before study treatment. (Occasional smoking, such as 1-5
             cigarettes per week, or similar amount of nicotine, is allowed).

          -  Any medical condition that, in the opinion of the Investigator, would make the subject
             unsuitable for inclusion (e.g. chronic, relapsing or hereditary disease that may
             interfere with the outcome of the study.

          -  Other condition preventing the subject from entering the study in the Investigator's
             opinion, e.g. subjects not likely to avoid other facial aesthetic treatments, subjects
             anticipated to be unreliable, unavailable or incapable of understanding the study
             assessments or having unrealistic expectations of the treatment result.

          -  Study site personnel or close relatives of the study site personnel (e.g. parents,
             children, siblings and spouse) or employees at the Sponsor company.

          -  Participation in any other clinical study within 3 months before study treatment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Sattler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rosenpark Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martina Kerscher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hamburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rosenpark Research</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 26, 2015</study_first_submitted>
  <study_first_submitted_qc>March 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <results_first_submitted>June 26, 2019</results_first_submitted>
  <results_first_submitted_qc>September 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 6, 2019</results_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 2, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02403986/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>R. Vital Skinboosters Lidocaine (Three)</title>
          <description>Treatment with three initial sessions
Restylane Vital Skinboosters Lidocaine</description>
        </group>
        <group group_id="P2">
          <title>R. Vital Skinboosters Lidocaine (Two)</title>
          <description>Treatment with two initial sessions
Restylane Vital Skinboosters Lidocaine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>R. Vital Skinboosters Lidocaine (Three)</title>
          <description>Treatment with three initial sessions
Restylane Vital Skinboosters Lidocaine</description>
        </group>
        <group group_id="B2">
          <title>R. Vital Skinboosters Lidocaine (Two)</title>
          <description>Treatment with two initial sessions
Restylane Vital Skinboosters Lidocaine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.2" lower_limit="35" upper_limit="46"/>
                    <measurement group_id="B2" value="41.0" lower_limit="34" upper_limit="46"/>
                    <measurement group_id="B3" value="41.1" lower_limit="34" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Improved Participants on the Global Aesthetic Improvement Scale (GAIS)-Subject</title>
        <description>Subject assessment at follow-up visits of aesthetic change from baseline of the treated areas using the Global Aesthetic Improvement Scale (GAIS).
GAIS is a 5-graded scale: worse; no change; improved; much improved; or very much improved.
A clinically significant improvement was defined as a score of improved; much improved; or very much improved.</description>
        <time_frame>Baseline, 1 Month, 3 Months, 6 Months, 9 Months, 12 Months, 15 Months, 18 Months</time_frame>
        <population>At 1 Month after initial treatment, there were 24 participants in Group A and 25 participants in Group B. (26 and 27 respectively randomized, as reported in Participant Flow.)</population>
        <group_list>
          <group group_id="O1">
            <title>R. Vital Skinboosters Lidocaine (Three)</title>
            <description>Treatment with three initial sessions
Restylane Vital Skinboosters Lidocaine</description>
          </group>
          <group group_id="O2">
            <title>R. Vital Skinboosters Lidocaine (Two)</title>
            <description>Treatment with two initial sessions
Restylane Vital Skinboosters Lidocaine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Improved Participants on the Global Aesthetic Improvement Scale (GAIS)-Subject</title>
          <description>Subject assessment at follow-up visits of aesthetic change from baseline of the treated areas using the Global Aesthetic Improvement Scale (GAIS).
GAIS is a 5-graded scale: worse; no change; improved; much improved; or very much improved.
A clinically significant improvement was defined as a score of improved; much improved; or very much improved.</description>
          <population>At 1 Month after initial treatment, there were 24 participants in Group A and 25 participants in Group B. (26 and 27 respectively randomized, as reported in Participant Flow.)</population>
          <units>% improved participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7" lower_limit="73.0" upper_limit="99.0"/>
                    <measurement group_id="O2" value="80.0" lower_limit="59.3" upper_limit="93.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" lower_limit="57.8" upper_limit="92.9"/>
                    <measurement group_id="O2" value="72.0" lower_limit="50.6" upper_limit="87.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3" lower_limit="56.3" upper_limit="92.5"/>
                    <measurement group_id="O2" value="58.3" lower_limit="36.6" upper_limit="77.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3" lower_limit="54.6" upper_limit="92.2"/>
                    <measurement group_id="O2" value="50.0" lower_limit="29.1" upper_limit="70.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" lower_limit="58.1" upper_limit="94.6"/>
                    <measurement group_id="O2" value="60.9" lower_limit="38.5" upper_limit="80.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" lower_limit="58.1" upper_limit="94.6"/>
                    <measurement group_id="O2" value="68.2" lower_limit="45.1" upper_limit="86.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" lower_limit="58.1" upper_limit="94.6"/>
                    <measurement group_id="O2" value="77.3" lower_limit="54.6" upper_limit="92.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Improved Participants on the Global Aesthetic Improvement Scale (GAIS)-Investigator</title>
        <description>Investigator assessment at follow-up visits of aesthetic change from baseline of the treated areas using the Global Aesthetic Improvement Scale (GAIS).
GAIS is a 5-graded scale: worse; no change; improved; much improved; or very much improved.
A clinically significant improvement was defined as a score of improved; much improved; or very much improved.</description>
        <time_frame>Baseline, 1 Month, 3 Months, 6 Months, 9 Months, 12 Months, 15 Months, 18 Months</time_frame>
        <population>At 1 Month after initial treatment, there were 24 participants in Group A and 25 participants in Group B. (26 and 27 respectively randomized, as reported in Participant Flow.)</population>
        <group_list>
          <group group_id="O1">
            <title>R. Vital Skinboosters Lidocaine (Three)</title>
            <description>Treatment with three initial sessions
Restylane Vital Skinboosters Lidocaine</description>
          </group>
          <group group_id="O2">
            <title>R. Vital Skinboosters Lidocaine (Two)</title>
            <description>Treatment with two initial sessions
Restylane Vital Skinboosters Lidocaine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Improved Participants on the Global Aesthetic Improvement Scale (GAIS)-Investigator</title>
          <description>Investigator assessment at follow-up visits of aesthetic change from baseline of the treated areas using the Global Aesthetic Improvement Scale (GAIS).
GAIS is a 5-graded scale: worse; no change; improved; much improved; or very much improved.
A clinically significant improvement was defined as a score of improved; much improved; or very much improved.</description>
          <population>At 1 Month after initial treatment, there were 24 participants in Group A and 25 participants in Group B. (26 and 27 respectively randomized, as reported in Participant Flow.)</population>
          <units>% improved participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="85.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="96.0" lower_limit="79.6" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8" lower_limit="78.9" upper_limit="99.9"/>
                    <measurement group_id="O2" value="92.0" lower_limit="74.0" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6" lower_limit="61.2" upper_limit="95.0"/>
                    <measurement group_id="O2" value="87.5" lower_limit="67.6" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" lower_limit="59.7" upper_limit="94.8"/>
                    <measurement group_id="O2" value="70.8" lower_limit="48.9" upper_limit="87.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4" lower_limit="65.1" upper_limit="97.1"/>
                    <measurement group_id="O2" value="87.0" lower_limit="66.4" upper_limit="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.2" lower_limit="76.2" upper_limit="99.9"/>
                    <measurement group_id="O2" value="95.5" lower_limit="77.2" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="90.9" lower_limit="70.8" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>R. Vital Skinboosters Lidocaine (Three)</title>
          <description>Treatment with three initial sessions
Restylane Vital Skinboosters Lidocaine</description>
        </group>
        <group group_id="E2">
          <title>R. Vital Skinboosters Lidocaine (Two)</title>
          <description>Treatment with two initial sessions
Restylane Vital Skinboosters Lidocaine</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Implant site swelling</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Implant site nodule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Implant site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menopausal symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cecilia Skoglund, Manager Study strategy and publications</name_or_title>
      <organization>Q-Med AB</organization>
      <phone>46 18 474 9000</phone>
      <email>cecilia.skoglund@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

